drugset / Trial / NCT05451433

The Effect of Saccharomyces Boulardii in Clinical Presentation and Quality of Life Patient With IBS

NCT05451433

RandomizedParallel-groupTriple-blindTreatment

Summary

This study aims to compare the effectiveness of Saccharomyces Boulardii vs Placebo in patient with Irritable Bowel Syndrome

Timeline

Start
2022-08-01
Primary completion
2022-08-01
Completion
2022-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Saccharomyces boulardii Other / unclassified 250 mg